The Effects Of Arsenic Trioxide (As₂O₃) On Human Megakaryocytic Leukemia Cell Lines With a Comparison of its Effects on Other Cell Lineages

References

• Shen Z X, Chen G Q, Ni J H, Li X S, Xiong S M, Qiu Q Y, Zhu J, Tang W, Sun G L, Yang K Q, Chen Y, Zhou L, Fang Z W, Wang Y T, Ma J, Zhang P, Zhang T D, Chen S J, Chen Z, Wang Z Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360
   PubMed Web of Science ®Google Scholar
• Soignet S L, Maslak P, Wang Z -G, Jhanwar S, Calleja E, Dardashti L J, Corso D, DeBlasio A, Gabrilove J L, Schein-berg D A, Pandolfi P P, Warrell R P, Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–1348
   PubMed Web of Science ®Google Scholar
• Mu Z M, Chin K V, Liu J W, Lozano G, Chang K S. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol 1994; 14: 6858–6867
   PubMed Web of Science ®Google Scholar
• Chen G Q, Zhu J, Shi X G, Ni J H, Zhong H J, Si G Y, Jin X L, Tang W, Li X S, Xong S M, Shen Z X, Sun G L, Ma J, Zhang P, Zhang T D, Gazin C, Naoe T, Chen S J, Wang Z Y, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996; 88: 1052–1061
   PubMed Web of Science ®Google Scholar
• Chen G Q, Shi X G, Tang W, Xiong S M, Zhu J, Cai X, Han Z G, Ni J H, Shi G Y, Jia P M, Liu M M, He K L, Niu C, Ma J, Zhang P, Zhang T D, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang Z Y, de Thé H, Chen S J, Chen Z. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): 1. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345–3353
   PubMed Web of Science ®Google Scholar
• Shao W, Fanelli M, Ferrara F F, Riccioni R, Rosenauer A, Davison K, Lamph W W, Waxman S, Pelicci P G, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller W H, Jr. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARa protein in acute promyelocytic leukemia cells. J Natl Cancer lnst 1998; 90: 124–133
   PubMed Web of Science ®Google Scholar
• Wang Z -G, Rivi R, Delva L, König A, Scheinberg D A, Gambacorti-Passerini C, Gabrilove J L, Warrell R P, Jr, Pandolfi P P. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARa independent manner. Blood 1998; 92: 1497–1504
   PubMed Web of Science ®Google Scholar
• Rousselot P, Labaume S, Marolleau J P, Larghero J, Noguera M H, Brouet J C, Fermand J P. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999; 59: 1041–1048
   PubMed Web of Science ®Google Scholar
• Zhu X H, Shen Y L, Jing Y K, Cai X, Jia P M, Huang Y, Tang W, Shi G Y, Sun Y P, Dai J, Wang Z Y, Chen S J, Zhang T D, Waxman S, Chen Z, Chen G Q. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91: 772–778
   PubMed Web of Science ®Google Scholar
• Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Naka-mura S, Takeshita K, Takeshita A, Ohno R. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998; 12: 1383–1391
   PubMed Web of Science ®Google Scholar
• Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, Yagi K. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br J Haematol 1998; 102: 1055–1060
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, El-Sabban M E, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haidar J H, Hermine O, de Thé H. Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lym-photropic virus type I-transformed cells. Blood 1999; 93: 278–283
   PubMed Web of Science ®Google Scholar
• Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999; 455: 59–62
   PubMed Web of Science ®Google Scholar
• Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen J P, Han Z C. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 1999; 27: 845–852
   PubMed Web of Science ®Google Scholar
• Wyllie A H. Apoptosis and carcinogenesis. Eur J Cell Biol 1997; 73: 189–197
   PubMed Web of Science ®Google Scholar
• Rudel T, Bokoch G M. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 1997; 257: 1571–1574
   Web of Science ®Google Scholar
• Quignon F, De Bels F, Koken M, Feuteun J, Ameisen J C, de Thé H. PML induces a caspase-independent cell death process. Nat Genet 1998; 20: 2559–2565
   Google Scholar
• König A, Wrazel L, Warrell R P, Jr, Rivi R, Pandolf'i P P, Jakubowski A, Gabrilove J L. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997; 90: 562–570
   PubMed Web of Science ®Google Scholar
• Dai J, Weinberg R S, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268–277
   PubMed Web of Science ®Google Scholar
• Chen Y C, Lin-Shiau S Y, Lin J K. Involvement of reactive oxygen species and caspase 3 activation in arsen-ite-induced apoptosis. J Cell Physiol 1998; 177: 324–333
   PubMed Web of Science ®Google Scholar
• Muller S, Matunis M I, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998; 17: 61–70
   PubMed Web of Science ®Google Scholar
• Zhu J, Koken M HM, Quignon F, Chelbi-Alix M K, Degos L, Wang Z Y, Chen 2, de Thé H. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 3978–3983
   PubMed Web of Science ®Google Scholar
• Melnick A, Licht J D. Deconstructing a disease: RARa its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167–3215
   PubMed Web of Science ®Google Scholar
• Chen 2, Wang Z Y, Chen S J. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther 1997; 76: 141–149
   PubMed Web of Science ®Google Scholar
• Daniel M T, Koken M, Romagnk O, Barbey S, Bazarbachi A, Stadler M, Guillernin M C, Degos L, Chomienne C, de Thé H. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 1993; 82: 1858–1867
   PubMed Web of Science ®Google Scholar
• Lam Y W, Ammerlaan W, Kroese F, Opstelten D. Cell type- and differentiation stage-dependent expression of PML domains in rat, detected by monoclonal antibody HIS55. Exp Cell Res 1995; 221: 344–356
   PubMed Web of Science ®Google Scholar
• Nason-Buchenal K, Gandini D, Botto M, Allopenna J, Seale J RC, Cross N CP, Goldman J M, Dmitrovsky E, Pandolfi P P. Interferon augments PML and PMLRARα expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line. Blood 1996; 88: 3926–3936
   PubMed Web of Science ®Google Scholar
• Koken M H, Puvion-Dutilleul F, Guillemin M C, Viron A, Linares-Cruz G, Stuurman N, de Jong L, Szostecki C, Calvo F, Chomienne C, Degos L, Puvion E, de Thé H. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 1994; 13: 1073–1083
   PubMed Web of Science ®Google Scholar
• Cavigelli M, Li W W, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-I activity by inhibiting a JNK phosphatase. EMBO J 1996; 15: 6269–6279
   PubMed Web of Science ®Google Scholar
• Chen W, Martindale J L, Holbrook N J, Liu Y. Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and She. Mol Cell Biol 1998; 18: 5178–5188
   PubMed Web of Science ®Google Scholar
• Jing Y, Dai J, Chalmers-Redmen R ME, Tatton W G, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102–2111
   PubMed Web of Science ®Google Scholar
• Stemsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ott-mann O G, Ruthardt M. PIC-I ISUMO-I -modified PML-retinoic acid receptor α mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 1999; 19: 5170–5178
   PubMed Web of Science ®Google Scholar
• Li Y M, Broome J D. Arsenic targets tubulins to induce apotosis in myeloid leukemia cells. Cancer Res 1999; 59: 776–780
   PubMed Web of Science ®Google Scholar
• Sato T, Ota S, Kakuda H, Miura N, Niimi H, Ito M, Asai T, Tsuruo T, Fuse A. Expression of multidrug resistant gene (mdr-1/P-glycoprotein) in a megakaryoblastic leukaemia cell line CMK, and its enhancement during megakaryocytic differentiation. Leuk Lymphoma 1995; 18: 515–520
   PubMed Web of Science ®Google Scholar
• San Miguel J F, Gonzalez M, Canizo M C, Ojeda E, Orfao A, Caballero M D, Moro M J, Fisac P, Lopez Borrasca A. Leukemias with megakaryoblastic involvement: clinical, hematologic, and immunologic characteristics. Blood 1988; 72: 402–407
   PubMed Web of Science ®Google Scholar
• Cripe L D, Hromas R. Malignant disorders of meg-akaryocytes. Semin Hematol 1998; 35: 200–209
   PubMed Web of Science ®Google Scholar
• Murphy S. Diagnostic criteria and prognosis in poly-cythemia Vera and essential thrombocythemia. Semin Hematol 1998; 36: 9–13
   Web of Science ®Google Scholar